Mucosal immunoregulation and inflammatory bowel disease: New insights from murine models of inflammation

Scandinavian Journal of Immunology

Volumn 48, Issue 5, 1998, Pages 453-458

  Strober, W ^a,e   Fuss, I J ^a   Ehrhardt, R O ^b   Neurath, M ^c   Boirivant, M ^d   Ludviksson B R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b PROTEIN DESIGN LABS INC   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CYTOKINE ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; OXAZOLONE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AUTOIMMUNITY; CLONAL ANERGY; CYTOKINE RELEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ENTERITIS; GENE DELETION; HELPER CELL; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LYMPHOCYTIC INFILTRATION; MOUSE; MUCOSA INFLAMMATION; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; MICE;

EID: 0031763281     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Crohn BB, Ginsberg L, Oppenheimer GD. Regional enteritis. A pathological and clinical entity. JAMA 1932;99:1323-9.
2. Wilks S. The morbid appearance of the intestine of Miss Banks. Med Times Gazette 1859;2:264-9.
3. Kirsner JB. Experimental 'colitis' with particular reference to hypersensitivity reactions in the colon. Gastroenterol 1961;40: 307-12.
4. Kraft SC, Fitch FW, Kirsner JB. Histologic and immunohistochemical features of Aver 'colitis' in rabbits. Am J Pathol 1963;43:913-23.
5. Cave DR, Kirsner JB. Animal models of inflammatory bowel disease. Gastroenterol 1979;17 (Suppl.):125-35.
6. Perlmann P, Hammarström S, Lagercrantz R, Gustafsson BE. Antigen from colon of germ free rats and antibiotics in human ulcerative colitis. Ann New York Acad Sci 1965;124:377-94.
7. Broberger O, Perlmann P. Autoantibodies in human ulcerative colitis. J Exp Med 1959;110:657-74.
8. James SP, Harriman GR, Lycke NY, Elwood LJ, Strober W. The immunopathogenesis of gastrointestinal and hepatobiliary diseases: T lymphocytes that express CD4 and the alpha beta-T cell receptor but lack Thy-1. Preferential localization in Peyer's patches. JAMA 1992;268:2910-7.
9. James SP, Strober W, Quinn TC, Danovitch SH. Crohn's disease. New concepts of pathogenesis and current approaches to treatment. Dig Dis Sci 1987;32:1297-310.
10. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in seid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;1:553-62.
11. Powrie F, Mason D. OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset [published erratum appears in J Exp Med 1991; 173:1037]. J Exp Med 1990;172:1701-8.
12. Sundberg JP, Elson CO, Bedigian H, Birkenmeier EH. Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterol 1994;107:1726-35.
13. Spiegel AM, Elson CO, Sartor RB, Tennyson GS, Riddell RH. G protein gene knockout hits the gut. Experimental models of inflammatory bowel disease. Nat Med 1995;1:522-4.
14. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
15. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
16. Mombaerts P, Mizoguchi E, Grusby MJL, Glimcher H, Bahan AK. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993;75:275-82.
17. Davidson NJ, Leach MW, Fort MM et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996;184:241-51.
18. Shanahan F, Davidson NJ, Leach MW et al. Cadherins, inflammatory bowel disease, and neoplasia. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. Gastroenterol 1996;111:261-2.
19. Ehrhardt RO, Ludviksson BR, Gray B, Neurath M, Strober W. Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol 1997;158:566-73.
20. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
21. Kosiewicz MM, Krishnan A, Shah M et al. Characterizastion of a new spontaneous murine model of inflammatory bowel disease. Gastroenterol 1998:114:G4142.
22. Fuss IJ, Neurath M, Boirivant M et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-70.
23. Neurath MF, Fuss I, Schürmann G et al. Upregulation of the IL-12/ STAT-4 signaling pathway distinguishes Crohn's disease from ulcerative colitis. Gastroenterol 1998;114:G4299.
24. Mizoguchi A, Mizoguchi E, Chiba C et al. Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease. J Exp Med 1996;183:847-56.
25. Fuss IJ, Boirivant M, Chu AC, Strober W. Oxazolone-induced colitis: an animal model of ulcerative colitis treatable with antibodies to IL-4. Gastroenterol 1998;114:G4020.
26. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunol 1993;78:127-31.
27. West GA, Matsuura T, Levine AD, Klein JS, Fiocchi C. Interleukin-4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterol 1996;110:1683-95.
28. Lúdvíksson BR, Ehrhardt RO, Fuss IJ, Strober W. Mucosal and thymic dysregulation. Role in human intestinal inflammation. The Immunologist 1997;5:202-9.
29. Bouma G, Crusius JBA, Pool MO et al. Secretion of tumor necrosis factor α and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles: relevance for inflammatory bowel disease. Scand J Immunol 1996;43:456-63.
30. Satsangi J, Parkes M, Louis E et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7, and 12. Nat Genet 1996;14:199-202.
31. Ohmen JD, Yang HY, Yamamoto KK et al. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease but not in ulcerative colitis. Hum Mol Genet 1996;5:1679-83.
32. Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996;183: 2605-16.
33. Elson CO, Beagley KW, Sharmanov AT et al. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 1996;157:2174-85.
34. Ludviksson BR, Ehrhardt RO, Strober W. TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonie inflammation in IL-2-deficient mice. J Immunol 1997;159:3622-8.
35. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB (low) CD4+ T cells. J Exp Med 1996;183:2669-74.
36. Strober W, Kelsall B, Fuss I et al. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today 1997;18:61-4.
37. Weiner HL. Oral tolerance. Proc Natl Acad Sci USA 1994;91: 10762-5.
38. Strober W, Kelsall B, Marth T. Oral tolerance. J Clin Immunol 1998; 18:1-30.
39. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance [published erratum in Nature 1995; 377:257]. Nature 1995;376: 177-80.
40. Marth T, Strober W. Oral tolerance and its modulation by anti cytokines. Res Immunol 1997;148:554-61.
41. Maeda H, Shiraishi A. TGF-beta contributes to the shift toward Th2 type responses through direct and IL-10-mediated pathways in tumor bearing mice. J Immunol 1996;156:73-8.
42. Takeuchi M, Kosiewicz MM, Alard P, Streilein JW. On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation. Eur J Immunol 1997;27:1648-56.
43. Seder RA, Marth T, Sieve MC et al. Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. J Immunol 1998;160:5719-28.
44. Schindler H, Diefenbach A, Rollinghoff M, Bogdan C. IFN-gamma inhibits the production of latent transforming growth factor-beta 1 by mouse inflammatory macrophages. Eur J Immunol 1998;28:1181-8.
45. Takeuchi M, Alard P, Streilein JW. TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells. J Immunol 1998;160:1589-97.
46. King C, Davies J, Mueller R et al. TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 1998;8:601-13.
47. Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest 1990;86:1255-60.
48. Sartor RB. The influence of normal microbial flora on the development of chronic mucosal inflammation. Res Immunol 1997;148: 567-76.
49. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55.
50. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996; 26:934-8.
51. Rath HC, Schultz M, Dielman LA et al. Selective vs. broad spectrum antibiotics in the prevention and treatment of experimental colitis in two rodent models. Gastroenterol 1998;114:G4367.
52. Cong Y, Brandwein SL, McCabe RP et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998;187:855-64.
53. Rath HC, Herfarth HH, Ikeda JS et al. Normal luminal bacteria, especially bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human h2 microglobulin transgenic rats. J Clin Invest 1996;98:945-53.
54. Russel MG, Dorant E, Volovics A et al. High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study: The South Limburg IBD Study Group. Dis Colon Rectum 1998;41:33-40.
55. Bjornsson S, Johannsson JH, Oddsson E. Inflammatory bowel disease in Iceland. 1980-89. A retrospective nationwide epidemiologic study. Scand J Gastroenterol 1998;33:71-7.
56. Fonager K, Sorensen HT, Olsen J. Change in incidence of Crohn's disease and ulcerative colitis in Denmark. A study based on the National Registry of Patients, 1981-92. Int J Epidemiol 1997; 26:1003-8.
57. Shivananda S, Lennard-Jones J, Logan R et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7.
58. Tragnone A, Corrao G, Miglio F, Caprilli R, Lanfranchi GA. Incidence of inflammatory bowel disease in Italy: a nationwide population-based study. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Int J Epidemiol 1996;25:1044-52.
59. Mate-Jimenez J, Munoz S, Vicent D, Pajares JM. Incidence prevalence ulcerative colitis Crohn's disease in urban rural areas Spain from 1981 to 1988. J Clin Gastroenterol 1994;18:27-31.